Analysis promising for keratectasia

Article

Diagnostic platform combines anterior surface topography, corneal tomography data

An analysis combining information from anterior Placido topography and corneal tomography obtained using a proprietary corneal imaging diagnostic platform (Orbscan II, Bausch + Lomb) has shown high sensitivity and specificity for discriminating between Placido negative eyes with forme fruste keratoconus (FFKC) and normal controls, and shows promise as a clinically useful tool for early diagnosis of keratectasia, said Dr Damien Gatinel, PhD.

"Our investigation shows that in eyes where there is no suspicion of keratoconus based on objective analysis of the anterior topography, evaluation of corneal tomography data may sometimes reveal an underlying ectatic condition," he added.

"Answering the question of what technique is superior for early detection of keratectasiasusceptible corneas requires welldesigned investigations. These must use a pertinent clinical model and appropriate statistical methods," Dr Gatinel said.

"These studies must include corneas with known keratectasia susceptibility, and to achieve maximum specificity and sensitivity, they must use discriminant analysis that evaluates the method's performance in separating the study groups and so minimizes false negatives and false positives," he explained.

Borrowing from Dr Stephen D. Klyce, PhD, who stated that the fellow eye of a patient with unilateral keratoconus should be considered as having FFKC, Dr Gatinel suggested that the fellow 'normal' represents the perfect false negative model for discriminant analysis studies.

"As Dr Klyce said, although the FFKC eye has no clinical findings of keratoconus and is Placido negative, it has genetic susceptibility to keratoconus and is considered to have subclinical keratoconus," he said.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.